Ultragenyx Announces Three Abstracts Accepted for Poster Presentation at 17th Annual World Muscle Society Congress

NOVATO, Calif., Oct. 10, 2012 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that three abstracts related to UX001 Sialic Acid Extended-Release for Hereditary Inclusion Body Myopathy were accepted for poster presentation at the 17th Annual World Muscle Society Congress October 9-12, 2012 in Perth, Australia.